Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies.

摘要: The activation state of an antitumor effector T cell in a tumor depends on the sum all stimulatory signals and inhibitory that it receives microenvironment. Accumulating data address increasing complexity these produced by myriad immune checkpoint molecules, cytokines, metabolites. While reductionist experiments have identified key molecules their importance signaling, less clear is integration allows cells to guide responses health disease. Mass spectrometry–based proteomics well poised offer such insights, including monitoring emergence resistance mechanisms immunotherapeutics during treatments. A major application this technology discovery characterization small-molecule agents capable enhancing response immunotherapeutic agents. Such approach would reinvigorate drug development aimed not at but rather tumor-resident producing dramatic durable responses. Cancer Immunol Res; 3(7); 714–20. ©2015 AACR .